

# DIABETIC MACULAR EDEMA TREATMENTS

Generic	Brand	Strength	Form	Adult Dose
<b>VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS</b>				
brolucizumab-dbl	<b>Beovu</b>	6mg/0.05mL	soln for intravitreal inj	6mg (0.05mL) every 6wks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12wks.
ranibizumab	<b>Lucentis</b>	6mg/mL (0.3mg), 10mg/mL (0.5mg)	soln for intravitreal inj	0.3mg (0.05mL of 6mg/mL) once a month (approx. 28 days)
	<b>Cimerli*</b>	6mg/mL (0.3mg), 10mg/mL (0.5mg)	soln for intravitreal inj	
<b>VEGF INHIBITOR + ANGIOPOIETIN-2 (ANG-2) INHIBITOR</b>				
faricimab-svoa	<b>Vabysmo</b>	120mg/mL	soln for intravitreal inj	<i>Regimen 1:</i> 6mg (0.05mL) once every 4wks for at least 4 doses, then may be adjusted by up to 4-week interval increments or reductions of up to 8-week interval increments based on CST and visual acuity evaluations through week 52; or <i>Regimen 2:</i> 6mg (0.05mL) once every 4wks for the 1st 6 doses, followed by 6mg (0.05mL) every 8wks over the next 28wks.
<b>VEGF INHIBITOR + HUMAN IgG1</b>				
afibercept	<b>Eylea</b>	2mg/0.05mL	soln for intravitreal inj	2mg (0.05mL) once every 4wks (approx. 28 days, monthly) for the 1st 5 doses, followed by 2mg (0.05mL) once every 8wks (2mos); some may need the monthly dosing after the 1st 5mos
<b>CORTICOSTEROIDS</b>				
dexamethasone	<b>Ozurdex</b>	0.7mg	intravitreal implant	One implant in each affected eye(s)
fluocinolone acetonide	<b>Iluvien</b>	0.19mg	intravitreal implant	One implant in each affected eye(s) <sup>†</sup>

## NOTES

\* Biosimilar to Lucentis.

† One implant is designed to release fluocinolone at an initial rate of 0.25mcg/day lasting 36mos.

Not an inclusive list of medications and/or official indications. Please see drug monograph at [www.eMPR.com](http://www.eMPR.com) and/or contact company for full drug labeling.

Created 10/2022